Hadas Nicole R.'s Form 4 filing
Akebia Therapeutics, Inc. (AKBA) · filed May 25, 2023
- Accession no.
- 0001562180-23-004504
- Filed
- May 25, 2023
- Trade date
- May 24-25, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $77.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hadas Nicole R.CIK 0001602396 | Officer (SVP, Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 24, 2023 | Common Stock | AGrant or awardAcquired | +200,000 | $0.00 | $0 | 587,530 | Direct | |
| May 25, 2023 | Common Stock | SSaleDisposed | −63,186 | $1.22 | −$77,086.92 | 524,344 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 24, 2023 | Common Stock | AGrant or awardAcquired | +200,000 | $0.00 | $0 | 200,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.